Your Feed

Filter by
See content from
Back to the latest
Thumbnail for MM-6 Trial: In-class transition to Ixazomib in Newly Diagnosed Myeloma | Robert Rifkin, MD | #ASH24
Playlist: ASH 2024

MM-6 Trial: In-class transition to Ixazomib in Newly Diagnosed Myeloma | Robert Rifkin, MD | #ASH24

Video details & playlist
Avatar
Dave Braucht
Multiple Myeloma Discussion • December 17, 2024
Managing Treatment Costs: A NORD Resource
AI-generated title
Looking for Copay Assistance with Amyloidosis US? The National Organization for Rare Disorders (NORD) can help! They offer copay assistance for: * Insurance premiums * Part B treatments (outpatient Medicare) * Part D prescription medications Contact NORD Today: Call: (203) 616-4326 Visit their website for more information: National Organization for Rare Disorders https://rarediseases.org
National Organization for Rare Disorders | NORD

National Organization for Rare Disorders | NORD

NORD is dedicated to supporting education, elevating care, advancing research, and driving policy for rare diseases

https://rarediseases.org
Thumbnail for IMWG Update: Long-Term Follow-Up, Teclistamab in Relapsed/Refractory #Myeloma | Carlyn Tan, MD | #ASH24
Playlist: ASH 2024

IMWG Update: Long-Term Follow-Up, Teclistamab in Relapsed/Refractory #Myeloma | Carlyn Tan, MD | #ASH24

Video details & playlist
Thumbnail for Talquetamab in BCMA-Exposed Relapsed/Refractory Multiple Myeloma | Hira Shaikh, MD | #ASH24
Playlist: ASH 2024

Talquetamab in BCMA-Exposed Relapsed/Refractory Multiple Myeloma | Hira Shaikh, MD | #ASH24

Video details & playlist
Thumbnail for Outcomes in Monoclonal Gammopathy of Renal Significance with Novel Agents | Hira Shaikh and Mehndi Dandwani | #ASH24
Playlist: ASH 2024

Outcomes in Monoclonal Gammopathy of Renal Significance with Novel Agents | Hira Shaikh and Mehndi Dandwani | #ASH24

Video details & playlist
Thumbnail for Outcomes in Monoclonal Gammopathy of Renal Significance with Novel Agents | Hira Shaikh and Mehndi Dandwani | #ASH24
Playlist: Multiple Myeloma

Outcomes in Monoclonal Gammopathy of Renal Significance with Novel Agents | Hira Shaikh and Mehndi Dandwani | #ASH24

Video details & playlist
Thumbnail for Circulating Tumor Cell As a Biomarker for Outcomes in Myeloma | Luca Bertamini, MD | #ASH24
Playlist: ASH 2024

Circulating Tumor Cell As a Biomarker for Outcomes in Myeloma | Luca Bertamini, MD | #ASH24

Video details & playlist
Thumbnail for Balancing Treatment Intervals and Quality of Life in Myeloma | Anna Fleischer | #ASH24
Playlist: ASH 2024

Balancing Treatment Intervals and Quality of Life in Myeloma | Anna Fleischer | #ASH24

Video details & playlist
Thumbnail for Trial of Iberdomide, A Novel CELMoD, In Smoldering Multiple Myeloma | Nisha Joseph, MD | #ASH24
Playlist: ASH 2024

Trial of Iberdomide, A Novel CELMoD, In Smoldering Multiple Myeloma | Nisha Joseph, MD | #ASH24

Video details & playlist
Thumbnail for Lovesick: Examining Couples Health During Myeloma Transplant | Ashley Rosko, MD | #ASH24
Playlist: ASH 2024

Lovesick: Examining Couples Health During Myeloma Transplant | Ashley Rosko, MD | #ASH24

Video details & playlist